Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Xuewen Liu

Showing results (131-140 of 146) with videos related to

Pageof 15
Sort By:
The Lancet. Respiratory Medicine|June 13, 2024
Garsorasib in patients with KRAS<sup>G12C</sup>-mutated non-small-cell lung cancer in China: an open-label, multicentre, single-arm, phase 2 trialZiming Li, Xiaomin Dang, Dingzhi Huang, et al.
Cancer Discovery|September 16, 2015
RICTOR Amplification Defines a Novel Subset of Patients with Lung Cancer Who May Benefit from Treatment with mTORC1/2 InhibitorsHaiying Cheng, Yiyu Zou, Jeffrey S Ross, et al.
Translational Lung Cancer Research|May 19, 2025
Efficacy and safety of finotonlimab plus docetaxel <i>vs.</i> docetaxel in previously treated advanced squamous cell non-small-cell lung cancer: a randomized, double-blinded, phase III trialBaohui Han, Lin Wu, Runxiang Yang, et al.
Lancet (London, England)|March 8, 2025
Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in ChinaAnwen Xiong, Lei Wang, Jianhua Chen, et al.
Future Oncology (London, England)|June 3, 2026
Plain language summary: comparing ivonescimab plus chemotherapy with tislelizumab plus chemotherapy in people with advanced squamous non-small cell lung cancer in the HARMONi-6 studyZhiwei Chen, Fang Yang, Zhou Jiang, et al.
European Journal of Cancer (Oxford, England : 1990)|December 2, 2025
Garsorasib in patients with KRAS G12C-mutated non-small-cell lung cancer: A pooled analysis of phase 1/2 studyZhengbo Song, Ziming Li, Yiping Zhang, et al.
Lancet (London, England)|May 31, 2026
Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy in advanced squamous non-small-cell lung cancer (HARMONi-6): interim overall survival analysis of a randomised, double-blind, phase 3 trial in ChinaShun Lu, Baogang Liu, Yongzhong Luo, et al.
Lancet (London, England)|October 22, 2025
Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (HARMONi-6): a randomised, double-blind, phase 3 trialZhiwei Chen, Fang Yang, Zhou Jiang, et al.
Thoracic Cancer|November 29, 2022
Chinese expert consensus on the diagnosis and treatment of HER2-altered non-small cell lung cancerShirong Zhang, Wenxian Wang, Chunwei Xu, et al.
Thoracic Cancer|September 18, 2023
Expert consensus on the diagnosis and treatment of RET gene fusion non-small cell lung cancer in ChinaXingxiang Pu, Chunwei Xu, Qian Wang, et al.
Pageof 15

Showing results (131-140 of 146) with videos related to

Sort By:
Pageof 15
The Lancet. Respiratory Medicine|June 13, 2024
Garsorasib in patients with KRAS<sup>G12C</sup>-mutated non-small-cell lung cancer in China: an open-label, multicentre, single-arm, phase 2 trialZiming Li, Xiaomin Dang, Dingzhi Huang, et al.
Cancer Discovery|September 16, 2015
RICTOR Amplification Defines a Novel Subset of Patients with Lung Cancer Who May Benefit from Treatment with mTORC1/2 InhibitorsHaiying Cheng, Yiyu Zou, Jeffrey S Ross, et al.
Translational Lung Cancer Research|May 19, 2025
Efficacy and safety of finotonlimab plus docetaxel <i>vs.</i> docetaxel in previously treated advanced squamous cell non-small-cell lung cancer: a randomized, double-blinded, phase III trialBaohui Han, Lin Wu, Runxiang Yang, et al.
Lancet (London, England)|March 8, 2025
Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in ChinaAnwen Xiong, Lei Wang, Jianhua Chen, et al.
Future Oncology (London, England)|June 3, 2026
Plain language summary: comparing ivonescimab plus chemotherapy with tislelizumab plus chemotherapy in people with advanced squamous non-small cell lung cancer in the HARMONi-6 studyZhiwei Chen, Fang Yang, Zhou Jiang, et al.
European Journal of Cancer (Oxford, England : 1990)|December 2, 2025
Garsorasib in patients with KRAS G12C-mutated non-small-cell lung cancer: A pooled analysis of phase 1/2 studyZhengbo Song, Ziming Li, Yiping Zhang, et al.
Lancet (London, England)|May 31, 2026
Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy in advanced squamous non-small-cell lung cancer (HARMONi-6): interim overall survival analysis of a randomised, double-blind, phase 3 trial in ChinaShun Lu, Baogang Liu, Yongzhong Luo, et al.
Lancet (London, England)|October 22, 2025
Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (HARMONi-6): a randomised, double-blind, phase 3 trialZhiwei Chen, Fang Yang, Zhou Jiang, et al.
Thoracic Cancer|November 29, 2022
Chinese expert consensus on the diagnosis and treatment of HER2-altered non-small cell lung cancerShirong Zhang, Wenxian Wang, Chunwei Xu, et al.
Thoracic Cancer|September 18, 2023
Expert consensus on the diagnosis and treatment of RET gene fusion non-small cell lung cancer in ChinaXingxiang Pu, Chunwei Xu, Qian Wang, et al.
Pageof 15